Vulvovaginal atrophy (VVA) resulting from estrogen deprivation at menopause often results in distressing vaginal dryness and dyspareunia. Fewer than 25% of affected women seek help for this condition citing embarrassment, cultural values, an aging or unavailable partner and concerns about use of estrogens following the Women's Health Initiative. Available non-hormonal treatments, such as moisturizers, while affording some relief can be messy to apply and do not prevent disease progression. A new oral selective estrogen receptor modulator, ospemifene, has been found to have strong estrogenic activity in vaginal tissues without adverse estrogenic effects at other sites.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jogc.2019.10.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial.
Breast Cancer Res Treat
December 2024
Comprehensive Cancer Center, Helsinki University Hospital, University of Helsinki, PO Box 180, 00290, Helsinki, Finland.
Purpose: This study aimed to analyze changes in serum estradiol (E2) levels during concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast cancer (BC) patients with vulvovaginal atrophy (VVA). Secondary objectives included assessing the effects of therapy on vaginal atrophy, quality of life (QoL) and menopause-related symptoms.
Methods: 20 postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks.
Hysterectomy without oophorectomy as a risk factor for genitourinary syndrome of menopause.
Int J Gynaecol Obstet
December 2024
Department of Menopause, Instituto Nacional de Perinatología, Mexico City, Mexico.
Anxiety and Depression in Japanese Patients with Genitourinary Syndrome of Menopause.
Int Urogynecol J
December 2024
Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan.
Introduction And Hypothesis: Women with genitourinary syndrome of menopause (GSM) may have anxiety and depression; however, this is unclear.
Methods: A total of 646 postmenopausal women undergoing treatment for menopausal symptoms were enrolled in this retrospective cross-sectional study. Questionnaire responses were recorded at the first visit, and participants were divided into GSM (≥1 moderate or severe GSM symptom) or no-GSM (without any moderate/severe symptoms) groups.
Photobiomodulation in post menopause genitourinary syndrome-Study protocol for a randomized, double-blind, controlled clinical protocol.
PLoS One
December 2024
Post Graduation Program in Biophotonics Medicine, Universidade Nove de Julho, São Paulo, SP, Brazil.
Introduction: Genitourinary Syndrome of Menopause (GSM) defines a set of symptoms associated with an estrogen deficit involving alterations in organs genitourinary and that results in several urinary, genital, and sexual alterations. Brazilian women live about a third of their life after menopause, where hormonal changes occur along with clinical manifestations, characterized by vaginal and vulvar dryness, burning sensation, discomfort, vulvovaginal irritation, lack of lubrication, dyspareunia and urinary incontinence. Fractionated photothermolysis and radiofrequency systems, alone or in combination were tested to improve GSM.
View Article and Find Full Text PDFUpdate on Genitourinary Syndrome of Menopause: A Scoping Review of a Tailored Treatment-Based Approach.
Life (Basel)
November 2024
Department of Medical and Surgical Sciences and Translational Medicine, PhD Course in "Translational Medicine and Oncology", Sapienza University of Rome, Viale dell'Università, 37, 00185 Rome, Italy.
Article Synopsis
- This scoping review examines treatment options for genitourinary syndrome of menopause (GSM), a commonly overlooked condition caused by reduced estrogen levels during menopause, leading to various symptoms impacting women's quality of life.
- The review analyzed 451 articles and ultimately included 19 studies that highlight first-line treatments like lubricants and moisturizers, as well as hormonal therapies such as selective estrogen receptor modulators and DHEA for managing severe symptoms.
- It emphasizes the importance of tailored therapy and effective communication to help women make informed treatment choices while calling for more research into GSM therapies, especially concerning safety in women with cancer histories.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!